Cited by 113Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models

Levites, Yona, Smithson, Lisa A., Price, Robert W., Dakin, Rachel S., Yuan, Bin, Sierks, Michael R., Kim, Jungsu, McGowan, Eileen, Kim Reed, Dana, Rosenberry, Terrone L., Das, Pritam, Golde, Todd E., Levites, Yona, Smithson, Lisa A., Price, Robert W., Dakin, Rachel S., Yuan, Bin, Sierks, Michael R., Kim, Jungsu, McGowan, Eileen, Kim Reed, Dana, Rosenberry, Terrone L., Das, Pritam, Golde, Todd E.·2006·The FASEB Journal

DOI 10.1096/fj.06-6463fje

Open this paper in CoChat — free account

Abstract

A number of hypotheses regarding how anti‐Aβ antibodies alter amyloid deposition have been postulated, yet there is no consensus as to how Aβ immunotherapy works. We have examined the in vivo binding properties, pharmacokinetics, brain penetrance, and alterations in Aβ levels after a single peripheral dose of anti‐Aβ antibodies to both wild‐type (WT) and young non‐Aβ depositing APP and BRI‐Aβ42 mice. The rapid rise in plasma Aβ observed after antibody (Ab) administration is attributable to prolongation of the half‐life of Aβ bound to the Ab. Only a miniscule fraction of Ab enters the brain, and despite dramatic increases in plasma Aβ, we find no evidence that total brain Aβ levels are significantly altered. Surprisingly, cerebral spinal fluid Aβ levels transiently rise, and when Ab:Aβ complex is directly injected into the lateral ventricles of mice, it is rapidly cleared from the brain into the plasma where it remains stable. When viewed in context of daily turnover of Aβ, these data provide a framework to evaluate proposed mechanisms of Aβ attenuation mediated by peripheral administration of an anti‐Aβ monoclonal antibody (mAb) effective in passive immunization paradigm. Such quantitative data suggest that the mAbs are either indirectly enhancing clearance of Aβ or targeting a low abundance aggregation intermediate.—Levites, Y., Smithson, L. A., Price, R. W., Dakin. R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Reed, D. K., Rosenberry, T. L., Das, P., Golde, T. E. Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models. FASEB J. 20, E2002–E2014 (2006)

Integrity signals

Registry

Crossref · 10.1096/fj.06-6463fje

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,722
P ROTOFIBRILS , P ORES , F IBRILS, AND N EURODEGENERATION : Separating the Responsible Protein Aggregates from The Innocent Bystanders
Caughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356

Show all 60 references

Research works printed but not linked: 3

Levites Y., 2005, Anti‐Abeta42 and Anti‐Abeta40 specific monoclonal antibodies attenuate amyloid deposition in an Alzheimer's disease mouse model, J. Clin. Invest, 116, 193, 10.1172/jci25410 · DOI
Lee E. B., 2005, Targeting Abeta oligomers by passive immunization with a conformation selective monoclonal antibody improves learning and memory in APP transgenic mice, J. Biol. Chem, 281, 4292, 10.1074/jbc.m511018200 · DOI
Gravina S. A., 1995, Amyloid beta protein (A beta) in Alzheimer's disease brain, Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J. Biol. Chem, 270, 7013

Sorted by citations

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Survey of the year 2003 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2004) · Journal of Molecular Recognition · doi:10.1002/jmr.726 · Cited by 506
Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448
Tau Aggregation and Its Interplay with Amyloid-β
Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1371-2 · Cited by 359
Advancing translational research with the Semantic Web
Ruttenberg, A., Clark, T., Bug, W., Samwald, M., Bodenreider, O., Chen, H., Doherty, D. W., Forsberg, K., Gao, Y. C., Kashyap, V., et al. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-s3-s2 · Cited by 330
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthé, C., Lent, R. W., Younkin, S. G., Younkin, L. H., Schiff, R. I., & Weksler, M. E. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.021 · Cited by 305
Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies
Shinohara, M., Tachibana, M., Kanekiyo, T., & Bu, G. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075796 · Cited by 297
Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles
Castillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278
Ultrasound treatment of neurological diseases — current and emerging applications
Leinenga, G., Langton, C. M., Nisbet, R. M., & Götz, J. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.13 · Cited by 274
Inhibition of Amyloid Formation
Härd, T., & Lendel, C. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.062 · Cited by 277
Immunotherapy for Alzheimer’s disease: Key Symposium: Immunotherapy for Alzheimer’s disease
Morgan, D. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02315.x · Cited by 225
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease
Britschgi, M., Olin, C. E., Johns, H. T., Takeda-Uchimura, Y., LeMieux, M. C., Rufibach, K., Rajadas, J., Zhang, H., Tomooka, B., Robinson, W. H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904866106 · Cited by 201
Brain Bioavailability of Human Intravenous Immunoglobulin and its Transport through the Murine Blood–Brain Barrier
St‐Amour, I., Paré, I., Alata, W., Coulombe, K., Goulet, C. R., Drouin‐Ouellet, J., Vandal, M., Soulet, D., Bazin, R., & Calon, F. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.160 · Cited by 194
Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model
Nisbet, R. M., Van der Jeugd, A., Leinenga, G., Evans, H. T., Janowicz, P. W., & Götz, J. (2017) · Brain · doi:10.1093/brain/awx052 · Cited by 187
Genetic Suppression of Transgenic APP Rescues Hypersynchronous Network Activity in a Mouse Model of Alzeimer's Disease
Born, H. A., Kim, J.-Y., Savjani, R. R., Das, P., Dabaghian, Y. A., Guo, Q., Yoo, J. W., Schuler, D. R., Cirrito, J. R., Zheng, H., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.5171-13.2014 · Cited by 178
Self-citation
Stigmasterol attenuates inflammatory response of microglia via NF-κB and NLRP3 signaling by AMPK activation
Jie, F., Yang, X., Yang, B., Liu, Y., Wu, L., & Lu, B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113317 · Cited by 161
Age-related decline in immunity: implications for vaccine responsiveness
Kumar, R., & Burns, E. A. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.4.467 · Cited by 156
Involvement of Fc Receptors in Disorders of the Central Nervous System
Okun, E., Mattson, M. P., & Arumugam, T. V. (2009) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8099-5 · Cited by 149
Intracranial Adeno-Associated Virus-Mediated Delivery of Anti-Pan Amyloid β, Amyloid β40, and Amyloid β42 Single-Chain Variable Fragments Attenuates Plaque Pathology in Amyloid Precursor Protein Mice
Levites, Y., Jansen, K. R., Smithson, L. A., Dakin, R. S., Holloway, V. M., Das, P., & Golde, T. E. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.2795-06.2006 · Cited by 128
Self-citation
Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies
Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., & Pilotto, A. (2012) · Immunotherapy · doi:10.2217/imt.11.170 · Cited by 130
Intracerebroventricular amyloid-β antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice
Thakker, D. R., Weatherspoon, M. R., Harrison, J., Keene, T. E., Lane, D. S., Kaemmerer, W. F., Stewart, G. R., & Shafer, L. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813404106 · Cited by 124
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
Self-citation
Robust amyloid clearance in a mouse model of Alzheimer’s disease provides novel insights into the mechanism of amyloid-β immunotherapy
Wang, A., Das, P., Switzer, R. C., Golde, T. E., & Jankowsky, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5077-10.2011 · Cited by 118
Self-citation
Disease modifying therapy for AD?1
Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117
Self-citation
Aβ Immunotherapy: Intracerebral Sequestration of Aβ by an Anti-Aβ Monoclonal Antibody 266 with High Affinity to Soluble Aβ
Yamada, K., Yabuki, C., Seubert, P., Schenk, D., Hori, Y., Ohtsuki, S., Terasaki, T., Hashimoto, T., & Iwatsubo, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2021-09.2009 · Cited by 117
Survey of the year 2006 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2007) · Journal of Molecular Recognition · doi:10.1002/jmr.862 · Cited by 116
Natural human antibodies to amyloid beta peptide
Szabo, P., Relkin, N. R., & Weksler, M. E. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.03.007 · Cited by 109
A highly insoluble state of Aβ similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice
Philipson, O., Hammarström, P., Nilsson, K. P. R., Portelius, E., Olofsson, T., Ingelsson, M., Hyman, B. T., Blennow, K., Lannfelt, L., Kalimo, H., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.022 · Cited by 108
Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: Distribution, dose-response, and mechanisms of delivery
Kumar, N. N., Lochhead, J. J., Pizzo, M. E., Nehra, G., Boroumand, S., Greene, G., & Thorne, R. G. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.006 · Cited by 95
Targeting Aβ and tau in Alzheimer's disease, an early interim report
Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89
Self-citation
Exposure Levels of Anti-LINGO-1 Li81 Antibody in the Central Nervous System and Dose-Efficacy Relationships in Rat Spinal Cord Remyelination Models after Systemic Administration
Pepinsky, R. B., Shao, Z., Ji, B., Wang, Q., Meng, G., Walus, L. R., Lee, X., Hu, Y., Graff, C. P., Garber, E. A., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183483 · Cited by 90
Open questions for Alzheimer’s disease immunotherapy
Golde, T. E. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt233 · Cited by 87
Self-citation
Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia
Malik, M., Chiles, J. W., Xi, H. S., Medway, C., Simpson, J. F., Potluri, S., Howard, D. S., Yu, L., Paumi, C. M., Mukherjee, S., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv092 · Cited by 84
Targeting Malignant Brain Tumors with Antibodies
Razpotnik, R., Novak, N., Šerbec, V. Č., & Rajčević, U. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01181 · Cited by 80
TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease
Chakrabarty, P., Li, A., Ladd, T. B., Strickland, M. R., Koller, E. J., Burgess, J. D., Funk, C. C., Cruz, P. E., Allen, M., Yaroshenko, M., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20180484 · Cited by 80
Self-citation
Ultrasound-mediated blood-brain barrier opening enhances delivery of therapeutically relevant formats of a tau-specific antibody
Janowicz, P. W., Leinenga, G., Götz, J., & Nisbet, R. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-45577-2 · Cited by 81
Systemic vaccination with anti‐oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg‐AD mice
Rasool, S., Martínez‐Coria, H., Wu, J., LaFerla, F. M., & Glabe, C. G. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12305 · Cited by 74
Chronic Intranasal Treatment with an Anti-Aβ30-42 scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease
Cattepoel, S., Hanenberg, M., Kulic, L., & Nitsch, R. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018296 · Cited by 74
Beta‐amyloid protein (25–35) disrupts hippocampal network activity: Role of Fyn‐kinase
Peña‐Ortega, F., Ordaz, B., Balleza‐Tapia, H., Bernal‐Pedraza, R., Márquez‐Ramos, A., Carmona‐Aparicio, L., & Giòrdano, M. (2009) · Hippocampus · doi:10.1002/hipo.20592 · Cited by 71
Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Penninkilampi, R., Brothers, H. M., & Eslick, G. D. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9722-5 · Cited by 71
Engineering and Pharmacology of Blood–Brain Barrier-Permeable Bispecific Antibodies
Stanimirovic, D. B., Kemmerich, K., Haqqani, A. S., & Farrington, G. K. (2014) · Advances in pharmacology · doi:10.1016/bs.apha.2014.06.005 · Cited by 74
Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult
Rodgers, S. P., Born, H. A., Das, P., & Jankowsky, J. L. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-28 · Cited by 69
Self-citation
Perispinal etanercept: Potential as an Alzheimer therapeutic
Griffin, W. S. T. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-3 · Cited by 66
Safety and Efficacy of Scanning Ultrasound Treatment of Aged APP23 Mice
Leinenga, G., & Götz, J. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00055 · Cited by 66
Enhanced Proteolytic Clearance of Plasma Aβ by Peripherally Administered Neprilysin Does Not Result in Reduced Levels of Brain Aβ in Mice
Walker, J. R., Pacoma, R., Watson, J., Ou, W., Alves, J., Mason, D. E., Peters, E. C., Urbina, H. D., Welzel, G., Althage, A., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3407-12.2013 · Cited by 59
Antibody-based therapy in Alzheimer's disease
Pul, R., Dodel, R. C., & Stangel, M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.552884 · Cited by 59
Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches
Kumar, N. N., Pizzo, M. E., Nehra, G., Wilken-Resman, B., Boroumand, S., & Thorne, R. G. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00548 · Cited by 60
The stress response neuropeptide CRF increases amyloid‐β production by regulating γ‐secretase activity
Park, H., Ran, Y., Jung, J. I., Holmes, O. W., Price, A. R., Smithson, L. A., Ceballos‐Diaz, C., Han, C. J., Wolfe, M. S., Daaka, Y., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201488795 · Cited by 57
Self-citation
Cyclic Peptides as Inhibitors of Amyloid Fibrillation
Luo, J., & Abrahams, J. P. (2014) · Chemistry - A European Journal · doi:10.1002/chem.201304253 · Cited by 56
Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency
Agadjanyan, M. G., Zagorski, K., Petrushina, I., Davtyan, H., Kazarian, K., Antonenko, M., Davis, J. L., Bon, C., Blurton-Jones, M. M., Cribbs, D. H., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0172-1 · Cited by 56
Biodistribution of [125I]-labeled therapeutic proteins: Application in protein drug development beyond oncology**All authors are current or former employees of Wyeth, Inc.
Vugmeyster, Y., DeFranco, D., Szklut, P., Wang, Q. L., & Xu, X. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21855 · Cited by 52
Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species
Vugmeyster, Y., Szklut, P., Wensel, D. L., Ross, J. E., Xu, X., Awwad, M., Gill, D. S., Tchistiakov, L., & Warner, G. L. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0405-x · Cited by 50
Experimental Investigation of Antibody-Mediated Clearance Mechanisms of Amyloid-β in CNS of Tg-SwDI Transgenic Mice
Vasilevko, V., Xu, F., Previti, M. L., Nostrand, W. E. V., & Cribbs, D. H. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.2788-07.2007 · Cited by 48
AAV‐mediated delivery of an anti‐BACE1 VHH alleviates pathology in an Alzheimer's disease model
Marino, M., Zhou, L., Rincón, M. Y., Callaerts‐Vegh, Z., Verhaert, J., Wahis, J., Creemers, E., Yshii, L., Wierda, K. D. B., Saito, T., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.201809824 · Cited by 46
Self-citation
Non-Invasive Delivery of Therapeutics into the Brain: The Potential of Aptamers for Targeted Delivery
Bukari, B. A., Samarasinghe, R. M., Noibanchong, J., & Shigdar, S. L. (2020) · Biomedicines · doi:10.3390/biomedicines8050120 · Cited by 46
Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer’s disease
Puli, L., Pomeshchik, Y., Olas, K., Malm, T., Koıstınaho, J., & Tanila, H. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-105 · Cited by 48
Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: Polymorphisms, structure, and function of complement receptor 1
Johansson, J. U., Brubaker, W. D., Javitz, H. S., Bergen, A. W., Nishita, D., Trigunaite, A., Crane, A., Ceballos, J., Mastroeni, D., Tenner, A. J., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.04.003 · Cited by 43
Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes
Goodwin, M. S., Sinyavskaya, O., Burg, F., O’Neal, V., Ceballos‐Diaz, C., Cruz, P. E., Lewis, J. M., Giasson, B. I., Davies, P., Golde, T. E., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.007 · Cited by 46
Self-citation
Fc effector of anti-Aβ antibody induces synapse loss and cognitive deficits in Alzheimer’s disease-like mouse model
Sun, X., Yu, X., Zhu, J., Li, L.-J., Zhang, L., Huang, Y., Liu, D., Ji, M., Sun, X., Zhang, L. L., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01273-8 · Cited by 42
Focused Ultrasound Mediated Opening of the Blood-Brain Barrier for Neurodegenerative Diseases
Fishman, P. S., & Fischell, J. M. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.749047 · Cited by 40
Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds
Joseph‐Mathurin, N., Dorieux, O., Trouche, S. G., Boutajangout, A., Kraska, A., Fontès, P., Verdier, J., Sigurdsson, E. M., Mestre‐Francés, N., & Dhénain, M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.013 · Cited by 38
Is passive immunization for Alzheimer's disease ‘alive and well’ or ‘dead and buried’?
Jicha, G. A. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902828285 · Cited by 40
Drugging DNA Damage Repair Pathways for Trinucleotide Repeat Expansion Diseases
Benn, C., Gibson, K. R., & Reynolds, D. S. (2020) · Journal of Huntington s Disease · doi:10.3233/jhd-200421 · Cited by 35
Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: 2. Relationship to amyloid β immunotherapy
Crane, A., Brubaker, W. D., Johansson, J. U., Trigunaite, A., Ceballos, J., Bradt, B. M., Glavis‐Bloom, C., Wallace, T. L., Tenner, A. J., & Rogers, J. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.04.015 · Cited by 34
Alzheimer amyloid-β- peptide disrupts membrane localization of glucose transporter 1 in astrocytes: implications for glucose levels in brain and blood
Hendrix, R. D., Ou, Y., Davis, J. E., Odle, A. K., Groves, T. R., Allen, A. R., Childs, G. V., & Barger, S. W. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.10.001 · Cited by 33
Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β
Toyn, J. H., & Ahlijanian, M. K. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt244 · Cited by 31
Emerging Promise of Immunotherapy for Alzheimer’s Disease: A New Hope for the Development of Alzheimer’s Vaccine
Kabir, M. T., Uddin, M. S., Mathew, B., Das, P. K., Perveen, A., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200422105156 · Cited by 32
Self-citation
Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies
Golde, T. E. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13583 · Cited by 29
Self-citation
Immunotherapy in Alzheimer's Disease: Where Do We Stand? Where Should We Go?
Rommy von Bernhardi, M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1248 · Cited by 28
Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs
Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27
Intracerebral but Not Peripheral Infection of Live Porphyromonas gingivalis Exacerbates Alzheimer’s Disease Like Amyloid Pathology in APP-TgCRND8 Mice
Aravindraja, C., Ravi, S., Liu, X., Goodwin, M. S., Veena, P., Godovikova, V., Fenno, J. C., Levites, Y., Golde, T. E., & Kesavalu, L. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063328 · Cited by 26
Self-citation
A short perspective on the long road to effective treatments for Alzheimer's disease
Reynolds, D. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14581 · Cited by 28
Structure of the LINGO-1–Anti-LINGO-1 Li81 Antibody Complex Provides Insights into the Biology of LINGO-1 and the Mechanism of Action of the Antibody Therapy
Pepinsky, R. B., Arndt, J. W., Quan, C., Gao, Y. L., Quintero‐Monzon, O., Lee, X., & Mi, S. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.211771 · Cited by 26
Oligomeric tau-targeted immunotherapy in Tg4510 mice
Schroeder, S. K., Joly‐Amado, A., Soliman, A. S., Sengupta, U., Kayed, R., Gordon, M. N., & Morgan, D. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0274-6 · Cited by 24
Diagnosis of Glioblastoma by Immuno-Positron Emission Tomography
Ruiz-López, E., Calatayud-Pérez, J., Castells-Yus, I., Gimeno-Peribáñez, M. J., Calvo, N. M., Morcillo, M. Á., & Schuhmacher, A. J. (2021) · Cancers · doi:10.3390/cancers14010074 · Cited by 25
Ultrasound-mediated delivery of novel tau-specific monoclonal antibody enhances brain uptake but not therapeutic efficacy
Bajracharya, R., Cruz, E., Götz, J., & Nisbet, R. M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.026 · Cited by 27
Clinical immunologic approaches for the treatment of Alzheimer's disease
Solomon, B. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.6.819 · Cited by 22
Limited Clearance of Pre-Existing Amyloid Plaques After Intracerebral Injection of Aβ Antibodies in Two Mouse Models of Alzheimer Disease
Tucker, S. M. F., Borchelt, D., & Troncoso, J. C. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31815f38d2 · Cited by 22
Amyloid-β Peptide-specific DARPins as a Novel Class of Potential Therapeutics for Alzheimer Disease
Hanenberg, M., McAfoose, J., Kulic, L., Welt, T., Wirth, F., Parizek, P., Strobel, L., Cattepoel, S., Späni, C. B., Derungs, R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.564013 · Cited by 22
A Human Monoclonal IgG That Binds Aβ Assemblies and Diverse Amyloids Exhibits Anti-Amyloid ActivitiesIn VitroandIn Vivo
Levites, Y., O’Nuallain, B., Puligedda, R. D., Ondrejčák, T., Adekar, S. P., Chen, C. S., Cruz, P. E., Rosario, A. M., Macy, S. D., Mably, A. J., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.5109-14.2015 · Cited by 21
Self-citation
Messenger RNA-encoded antibody approach for targeting extracellular and intracellular tau
Wongsodirdjo, P., Caruso, A. C., Yong, A., Lester, M. A., Vella, L. J., Hung, Y. H., & Nisbet, R. M. (2024) · Brain Communications · doi:10.1093/braincomms/fcae100 · Cited by 20
Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer’s disease
Lozupone, M., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Altamura, M., Bellomo, A., et al. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2348142 · Cited by 19
Anti-Aβ single-chain variable fragment antibodies exert synergistic neuroprotective activities inDrosophilamodels of Alzheimer's disease
Fernández-Fúnez, P., Zhang, Y., Sanchez-Garcia, J., de Mena, L., Khare, S., Golde, T. E., Levites, Y., & Rincón-Limas, D. E. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv321 · Cited by 19
Self-citation
Anti-Aβ single-chain variable fragment antibodies restore memory acquisition in a Drosophila model of Alzheimer’s disease
Martín‐Peña, A., Rincón-Limas, D. E., & Fernández-Fúnez, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-11594-2 · Cited by 18
Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice
Chiang, A. C. A., Fowler, S., Savjani, R. R., Hilsenbeck, S. G., Wallace, C. E., Cirrito, J. R., Das, P., & Jankowsky, J. L. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171484 · Cited by 18
Self-citation
Anti-Tau Antibodies: Hitting the Target
Golde, T. E., Lewis, J. M., & McFarland, N. R. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.009 · Cited by 17
Self-citation
Dietary Intake of Rosmarinic Acid Increases Serum Inhibitory Activity in Amyloid A Aggregation and Suppresses Deposition in the Organs of Mice
Lin, X., Watanabe, K., Kuragano, M., Kurotaki, Y., Nakanishi, U., & Tokuraku, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176031 · Cited by 16
Effects of NK-4 in a Transgenic Mouse Model of Alzheimer's Disease
Ohta, H., Arai, S., Akita, K., Ohta, T., & Fukuda, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030007 · Cited by 17
An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes
Futch, H. S., McFarland, K. N., Moore, B. D., Kuhn, M. Z., Giasson, B. I., Ladd, T. B., Scott, K. A., Shapiro, M. R., Nosacka, R. L., Goodwin, M. S., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190430 · Cited by 16
Self-citation
Impact of amyloid β aggregate maturation on antibody treatment in APP23 mice
Balakrishnan, K., Upadhaya, A. R., Steinmetz, J. L., Reichwald, J., Abramowski, D., Fändrich, M., Kumar, S., Yamaguchi, H., Walter, J., Staufenbiel, M., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0217-z · Cited by 15
Rapid Cerebral Amyloid Binding by Aβ Antibodies Infused into β-Amyloid Precursor Protein Transgenic Mice
Winkler, D. T., Abramowski, D., Danner, S., Zurini, M. G. M., Paganetti, P., Tolnay, M., & Staufenbiel, M. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.030 · Cited by 14
De la sérothérapie aux anticorps recombinants « nus »
Watier, H. (2009) · médecine/sciences · doi:10.1051/medsci/20092512999 · Cited by 13
Human Anti-Aβ IgGs Target Conformational Epitopes on Synthetic Dimer Assemblies and the AD Brain-Derived Peptide
Welzel, A. T., Williams, A. D., McWilliams‐Koeppen, H. P., Acero, L. F., Weber, A., Blinder, V., Mably, A. J., Bunk, S., Hermann, C., Farrell, M. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050317 · Cited by 13
Comprehensive evaluation of human-derived anti-poly-GA antibodies in cellular and animal models of C9orf72 disease
Jambeau, M., Meyer, K. D., Hruška-Plocháň, M., Tabet, R., Lee, C.-Z., Ray-Soni, A., Aguilar, C., Savage, K., Mishra, N., Cavegn, N., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2123487119 · Cited by 12
Crossing Barriers: Advancements in Macromolecular Therapeutics for Neurodegenerative Diseases and Strategies to Overcome the Blood–Brain Barrier
Alo, B., & Lamers, C. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00153 · Cited by 10
Deficits in hippocampal‐dependent transfer generalization learning accompany synaptic dysfunction in a mouse model of amyloidosis
Montgomery, K. S., Edwards, G. A., Levites, Y., Kumar, A., Myers, C. E., Gluck, M. A., Setlow, B., & Bizon, J. L. (2015) · Hippocampus · doi:10.1002/hipo.22535 · Cited by 10
Self-citation
Preclinical Comparison of the Amyloid-β Radioligands [11C]Pittsburgh compound B and [18F]florbetaben in Aged APPPS1-21 and BRI1-42 Mouse Models of Cerebral Amyloidosis
Waldron, A., Verhaeghe, J. A. J., Wyffels, L., Schmidt, M. E., Langlois, X., der Linden, A. V., Stroobants, S. G., & Staelens, S. G. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0833-9 · Cited by 9
Development of a novel radioimmunoassay to detect autoantibodies to amyloid beta peptides in the presence of a cross-reactive therapeutic antibody
Sloan, J. H., Ackermann, B. J., O’Dell, M., Bowsher, R. R., Dean, R. A., & Konrad, R. J. (2011) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2011.08.006 · Cited by 7
Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy
Levites, Y., Funk, C. C., Wang, X., Chakrabarty, P., McFarland, K. N., Bramblett, B., O’Neal, V., Liu, X., Ladd, T. B., Robinson, M., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00453-4 · Cited by 6
Self-citation
Clinical Trials for Disease‐Modifying Drugs Such as BACE Inhibitors
Hsu, H. H. (2010) · Wiley eBooks · doi:10.1002/9780470594087.ch9 · Cited by 6

Authors: Levites, Y., Smithson, L. A., Price, R. W., Dakin, R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Kim Reed, D., Rosenberry, T. L., Das, P., Golde, T. E., Levites, Y., Smithson, L. A., Price, R. W., Dakin, R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Kim Reed, D., Rosenberry, T. L., Das, P., & Golde, T. E.
Venue: The FASEB Journal
Publisher: Wiley
Published: 2006-10-26
Volume: 20
Issue: 14
Pages: 2576-2578
ISSN: 0892-6638 (ISSN-L)
1530-6860
DOI: 10.1096/fj.06-6463fje
OpenAlex: W2091723502
Semantic Scholar: 97676444e5cdee032b67a599961944ce98e967f9
Cited by: 113
References: 60
Citations by year: 2025: 1 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 3 · 2020: 7 · 2019: 3 · 2018: 8 · 2017: 8 · 2016: 4 · 2015: 8 · 2014: 10 · 2013: 8 · 2012: 7
FWCI: 4.11
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: The FASEB Journal (publishedVersion)
PubMed (publishedVersion)
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Funders: Mayo Foundation for Medical Education and Research
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: anti-amyloid beta antibodies, Alzheimer's disease, amyloid-beta immunotherapy, passive immunization, amyloid-beta clearance, pharmacokinetics, brain penetration, APP transgenic mice
MeSH terms: Alzheimer Disease, Animals, Antibodies, Monoclonal, Brain, Disease Models, Animal, Female, Immunization, Passive, Mice, Transgenic, Amyloid beta-Peptides, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks